Emerald Health Pharmaceuticals Receives IND Clearance to Begin Phase II Clinical Trial of EHP-101 for Relapsing Forms of Multiple Sclerosis

Emerald Health Pharmaceuticals, Inc. received clearance of its Investigational New Drug (IND) application by the FDA to begin enrolling patients in its Phase IIa clinical trial of EHP-101 for certain relapsing forms of multiple sclerosis (MS), specifically relapsing-remitting MS and active secondary progressive MS.